Loading…
Back to Compound Explorer
Secoisolariciresinol diglucoside (SDG)
Clinical trialMechanism of Action
Metabolized by colonic bacteria to enterodiol and enterolactone, which bind estrogen receptors (primarily ER-beta) with weak agonist/antagonist activity depending on endogenous estrogen levels; inhibits aromatase and 5-alpha-reductase; antioxidant through direct radical scavenging
Research Notes
FlaxseedWestern
SDG is the primary lignan in flaxseed, present at concentrations 75-800 times higher than other dietary sources. Clinical trials demonstrate cholesterol-lowering effects, blood pressure reduction, and potential breast cancer risk reduction. The LIGNANS trial showed significant reduction in hot flash frequency in postmenopausal women. Enterolactone levels correlate inversely with breast cancer risk in epidemiological studies.
Found In 1 Herb
3D Molecular Structure
Lignan glycoside (phytoestrogen)
Drag to rotate · Click atoms to explore
Secoisolariciresinol diglucoside (SDG)
Lignan glycoside (phytoestrogen)Sugar-bound molecules that control drug release in the body
Representative pattern: C₁₁H₁₄O₆
Atoms
Carbon
Oxygen
Live Research
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare practitioner before using any herbal product.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This content is for educational purposes only and is not a substitute for professional medical advice.